Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of oral JNJ-77242113 in moderate-to-severe plaque psoriasis
2021-005987-23Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing JNJ-77242113 with Placebo (2 arms). Primary endpoint: Proportion of participants achieving PASI 75. Started Mar 2022; status: completed.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2021-005987-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005987-23.